Judit Anido

Judit Anido has extensive experience driving the growth of biotech companies and advancing innovative cancer therapies. In leadership roles at Mosaic Biomedicals and Northern Biologics, she helped steer the development of MSC-1, an immuno-oncology program advanced through Phase 1 clinical trials and acquired by AstraZeneca in 2020. She also served as CEO of Nuage Therapeutics, a platform developing covalent small molecules targeting transcription factors driving cancer. Earlier in her career, Judit spent more than a decade conducting cancer research at the Vall d’Hebron Institute of Oncology. She holds a PhD in Biology from the University of Barcelona and an MBA from Duke University, with a Certification in Health Sector Management and a specialization in Entrepreneurship and Innovation.